Archive | Press Releases

RSS feed for this section

A New Study Published in The Annals of Thoracic Surgery: Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38% in Cardiac Surgical Patients Not Detected by Common Test in Use

New York, NY, April 19, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the publication of new research utilizing the BVA-100 blood volume analyzer that highlights significant, often unrecognized blood loss in cardiac surgery. The paper entitled “Measurement of Blood Loss in Cardiac Surgery: Still […]

Daxor to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House

New York, NY, April 4, 2018 Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces it will present at 3:00pm on Monday, April 9th at this year’s MicroCap Conference and will be available for meetings with investors on both April 9th and 10th. Michael Feldschuh, CEO of Daxor stated, […]

Daxor to Exhibit at the American Association of Heart Failure Nurses 2018 Advanced Heart Failure Symposium

New York, NY, March 22, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces it will exhibit for the first time at the American Association of Heart Failure Nurses Advanced Heart Failure Symposium, a medical education and medical technology exhibition held on March 23th and 24th in […]

New Data Showing Patient Care Individualized by Daxor’s Precision Blood Volume Analysis Reduces Heart Failure Readmissions by 56% and Mortality by over 80% Presented at the American College of Cardiology 2018 Annual Scientific Session

New York, NY, March 14, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the presentation of new research highlighting the significant benefits to patient outcomes through individualization of care guided by blood volume analysis (BVA). The study by John E. Strobeck, MD, PhD and Wayne […]

Daxor Corporation Announces Positive New Critical Care Research Highlighting Benefit from BVA Use; Daxor Corporation to Exhibit at the American College of Cardiology 2018 Annual Meeting

New York, NY, March 9, 2018 – Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, exhibited at the 2018 Society for Critical Care Medicine Annual Meeting from February 25-28 in San Antonio, Texas where research was presented highlighting the positive clinical benefits of the use of Daxor’s BVA-100 blood […]

Daxor Corporation Announces Rise in Kit Sales, New Device Sale, and Filing of Form N-CSR for 2017

New York, NY, March 8, 2018 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, filed a Form N-CSR disclosing its schedule of portfolio holdings as of December 31, 2017. In reporting its annual results for its medical device division, Daxor cited a 25% rise in kit sales related […]

Daxor Corporation Announces Share Buyback Program

New York, NY November 1, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announced today that an updated buyback program has been unanimously approved by Daxor’s Board of Directors. The Board of Directors of Daxor has voted to re-authorize the company’s share buyback for an amount of […]

Daxor Corporation Holds Annual Meeting Provides Business Growth Update and Strategic Plan

New York, NY June 29, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, (NYSE:DXR) held its annual meeting on June 27th in New York City, where it briefed investors on its progress in growing its medical technology operating company supplying the Daxor BVA-100 blood volume analysis device. […]

Daxor Corporation Announces Reinstatement of Compliance with the New York Stock Exchange (NYSE MKT LLC)

New York, NY June 26, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, received a letter from the New York Stock Exchange informing Michael Feldschuh, President and Chief Executive Officer of Daxor Corporation, that the Company is “Back in compliance with the NYSE MKT LLC continued listing […]

Daxor Corporation Announces Delay in Filing of Form N-CSR for December 31, 2016, and the Uniformed Services University of Health Sciences has been awarded a grant to study hemodilution utilizing Daxor’s BVA-100 device

NEW YORK, NY–(Marketwired – Apr 10, 2017) – On April 10, 2017, Daxor Corporation (NYSE MKT: DXR) received a letter from the NYSE MKT LLC (“the Exchange”) noting that it is not in compliance with the listing standards pertaining to the timing of SEC filings as set forth in Sections 134 and 1101 of the […]